(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau

(43) International Publication Date (10) International Publication Number 28 February 2008 (28.02.2008) PCT WO 2008/022468 Al

(51) International Patent Classification: [CA/CA]; 103-6190 Agronomy Road, Vancouver, British C07H 21/02 (2006.01) C12Q 1/02 (2006.01) Columbia V5T 1Z3 (CA). A61K 31/105 (2006.01) C12Q 1/18 (2006.01) (72) Inventors; and A61K 48/00 (2006.01) C12Q 1/42 (2006.01) (75) Inventors/Applicants (for US only): KRYSTAL, Gerald A61P 37/02 (2006.01) A61K 31/704 (2006.01) [CA/CA]; 5661 Elm Street, Vancouver, British Columbia C12N 15/55 (2006.01) A61K 31/337 (2006.01) V6N 1A3 (CA). ONG, Christopher [CA/CA]; 906-1 189 C12N 9/16 (2006.01) A61K 33/24 (2006.01) Howe Street, Vancouver, British Columbia V6Z 2X4 (CA). (21) International Application Number: MUI, Alice [CA/CA]; 301-3440 West Broadway, Vancou PCT/CA2007/001501 ver, British Columbia V6R 4R2 (CA). (22) International Filing Date: 24 August 2007 (24.08.2007) (74) Agent: CHATTERJEE, Alakananda; Gowling Lafleur (25) Filing Language: English Henderson LLP, 1055 Dunsmuir Street, Suite 2300, Van couver, British Columbia V7X IJl (CA). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 60/823,404 24 August 2006 (24.08.2006) US AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (71) Applicants (for all designated States except US): CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, BRITISH COLUMBIA CANCER AGENCY [CA/CA]; ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, 675 West 10th Avenue, Vancouver, British Columbia V5Z IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, 1L3 (CA). THE UNIVERSITY OF BRITISH COLUM¬ LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, BIA UNIVERSITY-INDUSTRY LIAISON OFFICE MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, [Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR TREATING MYELOSUPPRESSION

(57) Abstract: The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-containing inositol-5 '-phosphatase. PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, ZM, ZW. PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, Published: COMPOSITIONS AND METHODS FOR TREATING MYELOSUPPRESSXON

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application number 60/823,404, filed August 24, 2006, which is hereby incorporated by reference.

FIELD OF INVENTION

[0002] The invention provides compositions and methods for protection against and treatment of myelosuppression, More specifically, the invention provides inhibitors of SH2-containing inositol^' -phosphatase for protection against hemodepletion and treatment of myelosuppression.

BACKGROUND OF THE INVENTION

[0003] The phosphatidylinositol (PI) 3-kiaase (PDK) pathway plays a central role in regulating many biological processes, including survival and proliferation, through the generation of the potent second messenger, PIP3, This phospholipid is present at low levels in the plasma membrane of unstimulated cells but is rapidly synthesized fiotn PI-4,5-P2 by PI3K in response to a diverse array of extracellular stimuli (reviewed in H). This transiently generated PIP3 attracts pleckstrin homology (PH) domain- containing proteins, such as the s rvival/proliferatioϊi enhancing serine/threonine kinase Akt (also known as protein kinase B (PKB)), to the plasma membrane to mediate its effects (reviewed in 1,12), Activation of the PI3K/Akt pathway has been linked with resistance to chemotherapeutic drugs and to radiation u.and its down regulation via PBK inhibitors lowers e resistance of tumour cell lines to various types of therapy l '1$-To ensure that activation of the PI3K pathway is appropriately suppressed/terminated, the ubiquitously expressed tumour suppressor PTEN hydrolyzes 1 PIP3 to PI' 4 S-P2 while the hemopoietic restricted SH2-containing inositol-5 - phosphatase 1 (SHlPl) 3stem cell SHIP (sSHIP) (which is transcribed from a promoter between exons 5 and 6 of the SHIP gene and is expressed in embryonic l δ l6 stem (ES) cells and co-expressed s albeit at low levels, with SHIPl in HSCs ) , and the more widely expressed SHIP2 break it down to PI-3,4-P2. Within non- hemopoietic cells, PTEN and SHIP2 appear to be the key enzymes that keep PΪP3 levels suppressed while in hemopoietic cells, SHIPl is the central player,

[0004] SHIPl (also known as SHIP), has been implicated as a negative regulator of proliferation/survival, differentiation and end cell activation i hemopoietic cells by translocating to membranes following extracellular stimulation and hydrolysing the PBK- generated second messenger, PI-3.4,5-P3 (pπ»3) to Pl-3,4-P2 1. Myeloid progenitors in SHIP-/- mice display enhanced survival and proliferation and this results in an increased number of mature neutrophils and monocyte/ macrophages 2.

[0005] A major limitation in treating patients with chemotherapies or radiotherapies is the toxicity of these treatments to bone marrow (BM) cells. This leads to myelosupµressioa which results in anemia, requiring red blood cell transfusions, and increased susceptibility to infections because of a drop in white blood cells (leukocytes) and/or increased bleeding because of insufficient numbers of platelets. This myelosuppression limits the chemotherapy or radiation doses that can b e given, for example, to cancerpatients which in turn limits the likelihood of tumour eradication. Current strategies to replenish the BM deficit that follows these treatments include BM transplantation (which is costly and exposes patients to potentially lethal graft versus host disease) and the administration of cytokines such as erythropoietin (Epo or Epogen), G-CSF (Neupogen) and GM-CSF) to stimulate hemopoietic progenitor proliferation along various differentiation pathways. However, some patients do not respond to these cytokines and none of these treatments reverse the fall in platelet numbers. Additionally, the cost of administering even single cytokines is so prohibitive that most BM transplant facilities do not currently use them to narrow the "septic window" following these transplants and these patients are thus at high risk of dying from trivial infections.

SUMMARY OF THE INVENTION

[0006] The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-contaimng inositol-5'- phosphatase. [0007] In one aspec the invention provides a method of protecting a hemopoietic cell in a subject in need thereofby administering an effective amount of an inhibitor of a hemopoietic-restricted SH2-containing inositol-5'-phos ρhatase to the subject.

[0008] In alternative embodiments, the hemopoietic cell may be a hemopoietic progenitor c ll such as a myeloid progenitor cell or a lymphoid progenitor cell, or may be a mature cell. In alternative embodiments, the protecting includes decreasing cell death (e.g., apoptosis), In alternative embodiments, the cell death may be induced by chemotherapy or by radiotherapy, In alternative embodiments the hemopoietic-restricted SH2-containing inositol-5'- ρho$phatase may be a SHIPl molecule. In alternative embodiments, the subject may be a human. In alternative embodiments, the subject may have, or may be suspected of having, cancer (e,g,, a solid tumor). In alternative embodiments, the subject may be undergoing chemotherapy or radiotherapy. In alternative embodimente, the chemotherapy may be a cancer therapy (e.g., cisplatin, doxorubicin, or taxotere)- La alternative embodiments, the method farther comprises administering a chemotherapeutic agent (e,g,, a cancer therapeutic agent, such as cisplatin, doxorubicin, or taxotere) or administering a radiotherapy. The inhibitor may be administered before, during or after administration of said chemotherapeutic agent or said radiotherapy. The inhibitor may be a siRNA, e.g., a sequence consisting essentially of AAGAGTCAGGAAGGAGAGAAT (SEQ ID NO: 10) or AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11), or a small molecule.

[0009] In alternative aspects, the invention provides a method of treating myelosuppression (e.g,, immune suppression) in a subject in need thereof by administering an effective amount of an inhibitor of a hemopoietic-restricted SH2- containing inosϊtol-S '-phosphatase to the subject.

[0010] In alternative embodiments, the myelosuppression includes a decrease in hemopoietic progenitor cells or mature cells. In alternative embodiments, the treating includes increasing proliferation of a hemopoietic cell or includes reducing death of a hemopoietic cell. In alternative embodiments, the myelosuppression may be induced by chemotherapy or by radiotherapy. In alternative embodiments, the hemopoietic-restricted SH2-containing inositol-5 '-phosphatase maybe a SHIPl molecule. Ih alternative embodiments, the subject may have, or may be suspected of having, a cancer e.g., a solid tumor. In alternative embodiments, the subject may be a human. Ih alternative embodiments, the subject may be undergoing chemotherapy or radiotherapy. In alternative embodiments, the chemotherapy may be a cancer therapy. In alternative embodiments, the cancer therapy may be one o more of risplatin, doxorubicin, or taxotere. In alternative embodiments, the inhibitor may be administered after administration of said chemotherapy or said radiotherapy. In alternative embodiments, the inhibitor may be a siRNA or a small molecule. In alternative embodiments, the siRNA may consist essentially of the sequence

AAGAGTCAGGAAGGAGAGAAT (SEQ ID NO: 10) or

AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO; 11).

[001 1] In an alternative aspect, the invention provides an siRNA molecule consisting essentially of the sequence AAGAGTCAGGAAGGAGAGAAT (SEQ D NO: 10) or AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11).

[0012] In an alternative aspect, the invention provides a pharmaceutical composition comprising an siRNA molecule as described herein in combination with a pharmaceutically acceptable carrier.

[0013] In an alternative aspect the invention provides a pharmaceutical composition as described herein further comprising a chemomerapeutic agent. The chemotherapeutic agent may be one or more of cisplatiπ, doxorubicin, or taxotere.

[0014] In an alternative aspect, the invention provides a kit comprising an siRNA molecule as described herein, together with instructions for use in treating myelosuppression.

[001 5] In an alternative aspect, the invention provides a use of an inhibitor of a SH2- containing inositol-5'-phosphatase in the preparation of a medicament for protecting a hemopoietic cell in a subject in need thereof.

[0016] In an alternative aspect, the invention provides a use of an inhibitor of a SH2- containing inositoI-5 '-phosphatase in the preparation of a medicament for treating myelosuppression in a subject in need thereof. In alternative embodiments, the myelosuppression includes immune suppression.

[001 7] In an alternative aspect, the invention provides a method for screening for an inhibitor of ahemopoietic-restricted SH2-containing inositol-5' -phosphatase, by providing a test compound and a control compound; contacting a hemopoietic cell with the test compound or the control compound; and determining whether the test compound may be capable of increasing the survival or proliferation of the hemopoietic cell compared to the control compound; where a test compound that increases the survival or proliferation of the hemopoietic cell compared to the control compound may be an inhibitor of a SH2-coπtainmg inositol-5'- phosphatase.

[0018] This summary of the invention does not necessarily describe all features of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

[0020] Figures IA-H show siRNA-medieted inhibition of SHIP expression. (A-C) Immuπoblot analyses of the EL-4 cell line transduced with siRNAs to SHIP, as indicated or a control non-silencing siRNA (NS) and assessed for SHIP and control GAPDH protein expression on the indicated days; (D-E) Immunoblot analyses of the TFl hemopoietic progenitor cell line transduced with siRNA to SHIP (siSHIP or as indicated) or a control non-silencing siRNA (siNS or NS) and assessed for SHIP and control GAPDH protein expression on the indicated days. (F) Immυnoblot analyses of TFI cells traπsfected with siSHIP or siNS, stimulated with the cytokine GM-CSF for the indicated length of time, and probed with antibodies against SHIP, the PIP3 dependent kinase PKB or phospho PKB (Ser 473). (G) Graph of TF-I cells transfected with siSHIP (triangles) or siNS (squares) in the absence of growth factors. (H) Graph of TF-I cells transfected with siSHIP (open diamonds) and control siNS (solid diamonds), cultured in the presence of increasing concentrations of the growth promoting cytokine interleuMn-5 (IL-5), 2 days after siRNA transfectioπ, [0021] r« s >w8 a ar graph ofTFl cells ttaasfeotedwifli SHIP s A or

control si&NA and p life ra tion assessed by thymidine incorp αrβtioja. at the indicated concentrations of cispkim, do otiiMdn and tajrøterα

[0022] πr β3A-C show (A-B) Hienucleotide (SBQ ID NO; 1) and (C) eπ add (SEQ NO: 2) sequence of humBn SHIPl; eπBaπk Accession No. U5765G.

[0023] Mgwres 4A-C show (A-B) the nucleotide (SEQ BD NO: 3) and (C) a ύ add . sequence (SEQ ID NO; 4) of mouse SHIPI ; OeoBaak Accession No. U39203.

»ETArLED DESCKLF ΓΪØN

[0024] T e invsnfioa provides, inpsit, compositions i methods for Un - mo ul tiii SH2-eontaiaiilg i αaM-5 ' -piospbfllaac (S ) to protect hemopoietic cells, for example, during chemotherapy or radiotherapy of solid tumours end/or

a&t ipleratβthe re o e y of blood foπj jg cells jbUowing chenjo&firapy r

radiofiicnipy(e>g, ) o eoljd tumours). Reducing l v ls of SHIP in hamopoietle cells

dhssao i y- a/xd. celt death, SHIP l v l a be d e υaiαg SHTP inhibitots, e.g., sdBNA molecules selectivef σr SHIP. Reduction of IP using ϊRNA Increases the aurivivsl πd/αr proliferation of a wide iange of hemopoietic cells, including

platelets, aad enhance, the survival of hemopoietic cell? during oτfollowing cfasfflo r radio-therapy.

[0025] By "hemopoietic" or "I ie ato pai ' is meant Wood or "blood cells formed by

om poia σrhHaopoiPsisili bom? ai Wand peripheral blood,

[0026] Hemopoietic Stem Cells (HSCs) arc the most primitive present J the blood system d are capable of generating of e coll populations pi sβ t in the blood. HSCS ate. alsoci slbb of virtnaJly indefinite self n w l (i^unsmaifliaga

stain cell after w U ivision.) aad hav tfaβability glioύs b e e M - πievval n differeatiBtioa (ultin-atdy, into a mature bonwpoietic cull). HSCs al migrate s ul t ion, and are subject to rogidotkui by ajwutosis. HSCs areirare a are thought to account for an estimated 1 in 10,000 to 15,000 nucleated cells in the bone marrow, and an estimated 1 in 100,000 i the peripheral blood,

[0027] Hemopoietic Progenitor Cells (HPCs) are cells that are derived from and further differentiated from HSCs. When compared to HSCs, HPCs have a relatively reduced capacity to differentiate (they can generate only a subset of the possible lineages), although they are capable of extensive and rapid proliferation and can typically generate a large number of mature cells, Importantly, HPCs have a limited capacity to self-renew and therefore require regeneration from HSCs. A subset of HPCs can be held in a

"pool" i.e.3 where the cells are not actively cycling. HPCs are generally present in larger numbers than HSCs and can therefore be more rapidly mobilized or expanded in the hemopoietic recovery process, HPCs include Common Lymphoid Progenitors (CLPs)1, which in adults, have the potential to generate all of the lymphoid but not the rnyeloerythroid cells, and Common Myeloid Progenitors (CMPs), which have the potential to generate all of the mature myeloerythroid cells but not lymphoid cells.

[0028] HPCs give rise to the differentblood cell types of the myeloid and lymphoid lineages. The myeloerythroid lineage includes granulocytes (neutrophils, eosinophils, basophils), mast ceils, monocytes (histiocytes, macrophages, dendritic cells, Langerhans cells, microglia, Kupffer cells, osteoclasts), megakaryoblasts, megakaryocytes, erythrocytes, platelets and their various progenitors,eg.,colony forming units of the granulocytic/monocytic lineage (CFU-GM) 5burst forming units of the erythroid lineage (BFU-E), etc, The lymphoid lineage includes T-cells, B-cells, NK-cells and eir progenitors, etc.

[0029] HSCs and/or HPCs may be obtained from bone marrow, or from peripheral blood upon pre-treatment with cytokines, such as granulocyte colony stimulating factor (G-CSF), which induces release of HSCs and/or HPCs from the bone marrow. HSCs and/or HPCs may also be obtained from umbilical cord blood, placenta, fetal liver or spleen, etc. Mark-as specific for HSCs and/or HPCs are known in the art, as are assays for detecting and isolating HSCs and/Or HPCs and more differentiated hemopoietic cells. In alternative embodiments, HSCs are excluded from the methods and uses according to the invention. In alternative embodiments, the hemopoietic cell is a mature cell, a myeloid progenitor cell or a CMP. In alternative embodiments, the hemopoietic cell i$ a lymphoid cell, a lymphoid progenitor cell or a CLP.

[0030] Mature hemopoietic cells are tem nally differentiated cells and include neutrophils, eosinophils, basophils, histiocytes, macrophages dendritic cells, langerhans cells, microglia, Kupffer cells, osteoclasts, erythrocytes, platelets, T-cells, B-cells, and NK-cells. In alternative embodiments, lymphoid cells, e.g. NK cells, are excluded from the methods and uses according to the invention.

[0031] By '^protecting a hemopoietic cell" or "enhancing the resistance of a hemopoietic cell" is meant increasing the survival of a hemopoietic cell, such as a hemopoietic progenitor cell or a mature hemopoietic cell, by for example decreasing cell death (e.g. by apoptosis). It is to b understood that decreasing cell death includes the prevention or slowing of cell death and may be partial, as long as the subject exhibits less cell death when compared with a control or reference subject, sample or compound. The increase in survival of the hemopoietic cell, or decrease in cell death, maybe a change of any integer value between 10% and 90%, e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or may be over 100%, such as 200%, 300%, 500% or more, when compared with a control or reference subject, sample or compound. A control or reference subject, sample or compound maybe a subject, sample or compound that has not been, or is not being, exposed to an inhibitor of a SH2- containing inositol-5'-phosphatase, or an inhibitor of SHIPl

[0032] Ih alternative embodiments, "protecting a hemopoietic cell" or "enhancing the resistance of a hemopoietic celt" also includes increasing the proliferation of a hemopoietic cell, such as a hemopoietic progenitor cell or mature hemopoietic cell. It is to be understood that the increase in cell proliferation may be partial, as long as the subject exhibits more cell proliferation when compared with a control or reference subject, sample or compound. The increase in proliferation of the hemopoietic cell may be a change of any integer value between 10% and 90%, e.g,, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or maybe over 100%, such as 200%, 300%, 500% or more, when compared with a control or reference subject, sample or compound. A conttol or reference subject, sample or compound may be a subject, sample or compound that has not been, or is not being, exposed to an inhibitor of a SH2-contaiπiag inositol-S'-phosphatase, or an inhibitor of SHIPl.

[0033] MvelO-tt-ppression

[0034] Myelosuppression refers, in general, to a reduction in the production of blood cells. Myelosuppression therefore results in anemia, neutropenia, and thrombocytopenia.

[0035] Myelosuppression may result from a number of different factors, including stress, illness (such cancer), drugs (such as chetnotherapeutics), radiation therapy, infection (e.g., by HlV virus, other viruses or bacteria), environmental insults (such as accidental or deliberate exposure to chemicals, toxins, radiation, biological or chemical weapons), aging or other natural processes, etc.

[0036] Conventional treatments for myelosuppression include transfusion of blood, packed red blood cells, or platelets, or administration of growth factors such as erythropoietin, granulocyte colony stimulating factor (G-CSF), gramilocyte- macrophage colony stimulating factor (GM-CSF), interleukin-1 1, etc.

[0037] Myeloablation generally refers to a severe form of myelosuppression that is typically induced by treatment with a regimen of chemotherapeutic agents, optionally combined with irradiation, that destroys host blood cells and bone marrow tissues. Myeloablation is used to prepare subjects for autologous or allogeneic bone marrow or stem cell transplantation, to prevent an undesired immune response of host cells against the graft cells, or to destroy aberrant cells, such as in leukemias and lymphomas. Full myeloablation refers to the complete destruction of host blood cells and bone marrow tissue. I general, the immune suppression or myelosuppression induced by standard chemotherapy or radiotherapy regimens do not result in full myeloablation. Accordingly, in alternative embodiments, myeloablation or fall myeloablation is specifically excluded om the methods and uses according to the invention.

[0038] Immune suppression refers, in general, to a systemic reduction in immune function as evidenced by, for example, compromised in vitro proliferative response of B and T lymphocytes to mitogens, reduced natural killer (NK) cell cytotoxicity in vitro, reduced delayed type hypersensitivity (DTH) skin test responses to recall antigens. Immune suppression may result from a number of different factors, including stress, illness (such as cancer), drugs (such as dhemotherapeutics), radiation therapy, infection (e.g., by HIV virus, other viruses or bacteria), transplantation (e.g., of bone marrow, or stem ceils, or solid organs), environmental insults (such as accidental or deliberate exposure to chemicals, toxins, radiation, biological or chemical weapons), aging or other natural processes, etc.

SH2-coiataining inositols-phosphatase (SHIP) Molecules

[0039] SH2-containing inositol-S'-phosphatases (or SH2-containing phosphat dylinositol phosphatase) are phosphatases that selectively remove the phosphate from the 5-ρosition of the inositol ring in phosphoinositol-containing lipids.

11 [0040] The first such phosphatase identified, known as SHlP" or "SHIPl 1" is restricted to hemopoietic cells and is a 145 kDa protein that becomes both tyrosine phosphorylated and associated with the adaptor protein, She, after extracellular Stimulation of hemopoietic cells. SHIPl contains an N-terminal Src homology 2 (SH2) domain that binds preferentially to the amino acid sequence ρY(Y7D)X(I7I/V), a centrally located 5'-phosphatase that selectively hydrolyses PI-3,4,5 P and tas(l,3,4,5)A (IP ) in vitro, two NPXY amino acid sequences (hat, when phosphoiylated, bind the phosphotyrosine binding (PTB) domains of She, Dokl and Dok2 and proline-rich C-terminus that binds a subset of Src homology 3 (SH3)- containing proteins. SHIPl includes alternatively spliced forms (Lucas, D.M. and Rohrschneider, L.R. (1999) Blood 93, 1922-1933; Wolf, U Lucas, D,M., Algate, P.A. and Rohrschneider, LR. (2000) Genomics 69, 104-1 12) and C-teππinal truncations (Damen, J.E., Liu, L., Ware, M.D., Ermolaeva, M., Majerus, P.W. and Kiystal, G. (1998) Blood 92, 1199-1205). In alternative embodiments, SHIPl includes, without limitation, alternative splice forms and truncations. In alternative embodiments, SHIPl includes the sequences disclosed in U.S. Pat, No. 6,283,903 (issued to Krystal, May 29 2001), PCT publication WO 97/10252 (naming Rohrschneider and Lioubin as inventors and published March 20, 1997), or as set forth in SEQ ID NOs 1 to 4 or described in GenBank Accession Nos. U57650, U39203, U51742, NMj001017 ϊ 5, or other SHIPl mouse and human sequences, or SHIPl sequences from other species.

[0041] A 104 kDa protein temed "stem cell SHIP" or "sSHΪP" is only expressed i stem cells and HSCs (Tu, Z., Ninos, J.M., Ma, Z., Wang, J.-W., Lemos, M.P., Desponts, C , Ghansah, T , Howson, LM. and Kerr, W.G. (2001) Blood 98 2028- 2038), but not in HPCs. sSHIP is generated by transcription from a promoter within the intron between exons 5 and 6 of the SHIPl gene and is neither tyrosine phosphoryl&ted nor associated with She following stimulation, but binds consu'tutively to Gtb2. sSHIP is described in the GeπBank Accession No, AFl 84912.

[0042] SHIP2, which is a more widely expressed 150 kDa protein that also becomes tyrosine phosphorylated and associated with She in response to extracellular stimulation, exists, like SHIP and sSHIP, in lower-roolecular-mass forms and specifically hydrolyses the 5'-phosphate from Pl-3,4,5-P and TP4n vitro.

SHIP Inhibitors

{0043] SHIP inhibitors include compounds that block SHIP function or SHIP levels directly or indirectly by, for example, targeting of a SHIP signal transduction pathway; inhibition of SHIP activation; inhibition of SHIP mRNA transcription; increased SHIP mRNA degradation; or inhibition of SHIP protein translation, stability or activity. In alternative embodiments, SHIP inhibitors include small molecules, such as LY288975 (Abstract #1225, Blood 98: p291a, November 16, 2001), antibodies or fragments thereof, such as humanized anti-SHEPl antibodies, p pt and peptide fragments, uch as SHIPl dominant negative peptides and peptide fragments; ribozymes; and other nucleic acid molecules, including antisense oligonucleotides, shRNA, microRNA (miRNA)RNAi molecules, and siRNA molecules, m alternative embodiments, SHIP inhibitors include small molecules, such as LY288975 (Abstract #1225, Blood 98: p29la } November 16, 2001), antibodies or fragments thereof, such as humanized anti-SHϊP antibodies, peptides and peptide fragments, such as SHIPl dominant negative peptides and peptide fragments; ribθ2yme$; and other nucleic acid molecules, shRNA, microRNA (miRNA)RNAi molecules, and siRNA molecules.

I i [0044] Polynudeotide-based inhibitors of SHIP maybe single-stranded, double- stianded, or triplexes, In addition, they may be RNA, DNA, or contain both RNA and DNA. They may further include oligonucleotides and plasmids, including expression plasmids. In particular embodiments, expression plasmids express a polypeptide or polynucleotide inhibitor of SHIP, e.g., an siRNA, miRNA, sbRNA or antiaβnse oligonucleotide inhibitor of SHIP. In alternative embodiments, expression plasmids e pr s a polypeptide or polynucleotide inhibitor of SHIP, e.g,, an siRNA, miRNA, or shRNA, Additional SHIP inhibitors may be identified using commercially available libraries and standard screening and assay techniques. In alternative embodiments, SHIP inhibitors are not antisense oligonucleotide molecules.

[0045] In alternative embodiments, SHIP inhibitors specifically inhibit SHIPl, i.e., inhibit SHIPl with a greater specificity when compared to inhibition of sSHIP, SHIP2, or other molecules. In particular embodiments, SHIPl -specific inhibitors reduce SHIPl activity or expression to a level below 90% below 80% below 70%, below 60% below 50%, below 40%, below 30%, below 20%, below 10%, below 5%, or below 2% as compared to SHlPl activity or expression in the absence of said inhibitor, In related embodiments, SHIPl -specific inhibitors do not significantly reduce the expression or activity of sSHIP, SHIP2, or other molecules, πparticular embodiments, a SHIPl -specific inhibitor targets or binds a region of a SHlPl protein or polynucleotide that is not present in a sSHIP or SHIP2 protein or polynucleotide. For example, a SHIPl -specific inhibitor may target the ATG sequence at the start of the coding region for SHIPl or may target SHIPl polypeptide or polynucleotide sequences coiresponding to or encoding the approximately 300 bp SHIPl SH2 domain, which follows the ATG region. In alternative embodiments, a SHIPI- specific inhibitor may target any sequence from positions 1 to 505 of SEQ ID NO: 1 or 3, or may target SHIPl polypeptide or polynucleotide sequences coiresponding to or encoding the sequence from positions 1to 505 of SEQ ID NO: 1 or 3.

RNA Interference and siRNA

[0046] Expression of a gene or coding or non-coding region of interest may be inhibited or prevented using RNA interference (RNAi) technology, type of post- transcriptional gene silencing. RNAi may be used to create a functional "knockout", i.e. a system in which the expression of a gene or coding or non-coding region of interest is reduced, resulting in an overall reduction of the encoded product. As such, RNAi may performed to target a nucleic acid of interest or fragment or variant thereof, to in turn reduce its expression and the level of activity of the product which it encodes. Such a system may be used for functional studies of the product, as well as to treat disorders related to the activity of such a product, RNAi is described in for

example Hammond SM, et al. (2001) Nature Rev Gen 2: 110-1 19, Sharp PA. (2001) Genes Dev 15: 485-490, Caplen NJ, et al (200I)PrOc. Mw Acad. ScL USA 98: 9746-9747 and published US patent applications 20020173478 (Gewirtz; published November 21, 2002) and 20020132788 (Lewis et al.; published November 7, 2002), all of which are herein incorporated by reference. Reagents and kits for performing RNAi are available commercially from for example Ambion Inc. (Austin, TX, USA) and New England Biolabs Inc. (Beverly, MA, USA).

[0047] The initial agent for RNAi is a dsRNA molecule corresponding to a target nucleic acid. The dsRNA is then cleaved into short interfering RNAs (siRNAs) which are 21-23 nucleotides in length (19-21 bp duplexes, each with 2 nucleotide 3' overhangs). The enzyme effecting this first cleavage step is referred to as "Dicer" and

is categorized as a member of the RNase DI family of dsRNA-specific ribonucleases. Alternatively, RNAi may be directly introduced into the cell, or generated within the cell by introducing into the celi a suitable precursor (e.g. vector) of such an siRNA or siRNA-Iike molecule. An siRNA may then associate with other intracellular components to form an RNA-induced silencing complex (RISC). The RISC thus formed may subsequently target a transcript of interest via base-pairing interactions between its siRNA component and the target transcript by virtue of homology, resulting in the cleavage of the target transcript approximately 12 nucleotides from the 3' end of the siRNA, Thus the target mRNA is cleaved and the level of protein product it encodes is reduced.

[0048] RNAi may also be effected by the introduction of suitable in vitro synthesized siRNA or siRNA-like molecules into cells. RNAi may for example be performed using chemically-synthesized RNA (Brown D, et al, (2002) TechNotes9: 3-5), for which suitable RNA molecules may be chemically synthesized using known methods. siRNA molecules may comprise two RNA strands, or they may comprise an RNA strand and a DNA strand, as described, e.g.5in U.S Patent Application Publication No. 2004/0087526. Alternatively, suitable expression vectors may be used to transcribe such RNA either in vitro or in vivo, In vitro transcription of sense and antisense strands (encoded by sequences present on the same vector or on separate vectors) may be effected using for example T7 RNA polymerase, in which case the vector may comprise a suitable coding sequence operatøy-linked to a T7 promoter. The in vitro- transcribed RNA m y in embodiments be processed (e,g. using E. coli RNase IH) in vitro to a size conducive to RNAi. The sense and antisense transcripts combine to form an RNA duplex which is introduced into a target cell of interest. Other vectors may be used, which express short hairpin RNAs (shRNAs) which can be processed into siRNA-like molecules. Various vector-based methods are described in for example Brummelkamp TR, et al. (2002) Science 296:550-553, Lee NS, et al, (2002) Nature BiotechnoL 20:500-505, Miyagishi M, and Taira K. (2002) Nature Biotechnol. 20:497-500, Paddison PJ, et al. (2002). Genes & Dev, 16:948-958, Paul CP, et al.

(2002) Nature BiotechnoL 20:505-508, Sui G5 et al. (2002) Proc. Natl Acad, ScL USA 99:5515-5520, and Yu J-Y, et al. (2002) Proc. Natl Acad. Set. USA 99:6047-6052, all of which are herein incorporated by reference. Various methods for introducing such vectors into cells, either in vitro or in vivo (e.g. gene therapy) are known in the art.

[0049] Accordingly, SHIP expression maybe inhibited by introducing into or generating within a cell an siRNA or siRNA-like molecule corresponding to a SHIP- encoding nucleic acid or fragment thereof, or to an nucleic acid homologous thereto. In particular embodiments, the siRNA specifically targets SHIPl , In various embodiments such a method may entail the direct administration of the siRNA or siRNA-like molecule into a cell, or use of the vector-based methods described above.

[0050] The present invention specifically provides siRNAs consisting of, consisting essentially of or comprising at least 15 or more contiguous nucleotides of one of the SHIP genes, particularly the SHIPI, sSHIP, or SHIP2 genes of any species, including human and mouse. In particular embodiments, the siRNA comprises less than 30 nucleotides per strand, e.g., 21-23 nucleotides. The double stranded siRNA agent can either have blunt ends or may have overhangs of 1-4 nucleotides from one or both 3'

M ends of the agent, ϊ an embodiment, siRNA or siRNA-liJee molecules comprise a 19- 2 1 bp duplex portion, each strand having a 2 nucleotide 3' overhang.

[0051] Further, the siRNA may contain additional modifications. For example, the siRNA may either contain only naturally occumng ribonucleotide subunits, or it can be synthesized to contain one or more modifications to the sugar or base of one or o e of the ribonucleotide subunits that is included in the siRNA. The siRNA can be further modified so as to be attached to a ligaπd that is selected to improve stability, distribution or cellular uptake of the agent. One aspect of th present invention relates to a double-stranded siRNA comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl In certain embodiments, only one of the two oligonucleotide strands of the double-stranded oligonucleotide contains a non-natuiϊd nucleobase- ϊn certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently contain a non-natural nucleobase. Thus, in alternative embodiments, siRNA molecules may include a duplex having two strands and at least one modified nucleotide in the double-stranded region, whereeach strand is about 15 to about 60 nucleotides in length. Modified nucleotides suitable for use with siRNA are known.

[0052] siRNA molecules selective for a SHIP molecule may be determined using appropriate software programs, such as Promega (www .promega.com/siRNADesigner/proaram : Whitehead (jura.wi.nτ,it,edu/bioc/siRNAext/); Dharmacon

( ww.dharrnacon.c ' m/DegignC ntei/D signCenterPage.as s >: CSHL Jack Lin (wW-W.ic.sunvsb.edu/,sti-/sltilin/rnai.htm1); Ambion teww,ambion.eom/techlib/misc/siRNA ftnder.hlm[) GeneScript fwww-genscript.cain/ssl-m/app/rnaiV. Deqor (cluster-1 .mpi-cbg.de/Deqor/deqor.html) by, for example, entering the humaa SHIP sequence into the query field of the search engine. In alternative embodiments, an siRNA molecule selective for SHIPl includes one or more of the molecules listed in Table 1. Table 1

[0053] In alternative embodiments, the siRNA or siRNA-like molecule is substantially identical to a SHIP-encoding nucleic acid or a fragment or variant (or a fragment of a variant) thereof. In alternative embodiments, the sense strand of the siRNA or siRNA-like molecule is substantially identical to SEQ ID NOs: 1 or 3 or a fragment thereof (RNA having U in place of T residues of the DNA sequence). In alternative embodiments, the siRNA molecule targeting SHIP with the sequence AAGAGTCAGGAAGGAGAGAAT(SEQ ID NO: 10) or AAGAGTCAGGAAGGAGAAAAT(SEQ ID NO: 11) is used to treat myelosuppression.

[0054] In alternative embodiments, a RNA interference, shRNA or siRNA molecule selective for SHIP 1includes one or more of the sequences listed in Table 2, Table 3 lists sequences specific for human SHIPl,

s iRN A sequences from Cold Spring Harbor SNAi Codex (//codex.cshLedu/scriptfi/ πfiwmaiπ.pl)

Therapeutic Indications

[0055] As demonstrated herein, SHIP inhibitors, e.g., a SHIPl siKNA, may be used to reduce the expression or activity of SHEP in hematopoietic cells. In addition, SHIP inhibitors may be used to reduce or prevent apoptosis of hematopoetic cells, including hematopoietic progenitor cells in particular. Such apoptosis may b e naturally- occurring apoptosis or apoptosis induced by an agent or environmental stress, such as treatment with a chemotherapeutic agent or radiation. SHIP inhibitors may also be used to enhance proliferation of hematopoietic cells, including hematopoetic progenitor cells in particular.

[0056] SHIP inhibitors may be used to treat myelosuppression, e.g., immune suppression, Ih some embodiments, SHIP inhibitors may be used to accelerate or increase peripheral blood cell numbers after hemodepletion, for example, after chemotherapy or radiotherapy of solid tumours, or in any situation resulting in depletion of hemopoietic cells. In particular embodiments of me present invention, SHIPl -specific inhibitors are used to protect hematopoietic cells from cell death or increase their proliferation, e.g, before, during, or following treatment with one or more agents capable of inducing myelosuppression. Such SHIPl-specific inhibitors are advantageous as compared to drugs currently used to expand hematopoietic cells following chemotherapy, since SHIPl -specific inhibitors arepan-hematopoietic cell specific, while most currently used drugs act on only subset or particular type of hematopoietic cell. By "hemodepletion" is meant a decrease in hematopoietic cells, including white blood cells, red blood cells, and platelets.

[0057] In alternative embodiments, SHIP inhibitors may be used, for example, in combination with erythropoietin (EPO) to reverse the anemia that is associated with advanced solid cancers or to increase neutrophils during a systemic infection, hi alternative embodiments, SHIP inhibitors may be used to protect hemopoietic cells such as progenitors and mature blood cells, for example, before or during solid tumour chemotherapy and radiotherapy. Thus, in various embodiments, a SHIP inhibitor may be provided to a patient before, during, or after (or any combination thereof) treatment with a chemotherapeutic agent and/or radiotherapy.

[0058] hi one embodiment, a SHIPl inhibitor is used in combination with one or more chemotherapeutic agents and/or radiation to treat a solid tumor. The SHIPl inhibitor protects the hematopoietic cells from killing by the chemotherapeutic agent(s) and/or radiation, thereby allowing the patient to be treated with an increased total amount or higher dosage of the chemotherapeutic agent(s) and/or radiation. For example, one or more chemotherapeutic agents and/or radiation maybe administered to the patient in an amount or dosage higher than those normally used or approved, when provided in combination with a SHIP inhibitor.

[0059] In a related embodiment, SHIP inhibitor is provided to a patient in combination with another agent used to stimulate hematopoietic cell proliferation following chemotherapy, such as, e.g., granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), interleukin 3, or thrombopoieti . Li an alternative embodiment, a SHIP inhibitor is provided to a patient to expand hemopoietic cells, e.g., red blood cells, following dialysis. [0060] Cancers include solid tumours and non-solid tumours. Solid tumours include carcinomas, which are the predominant cancers and are cancers of epithelial cells or cells covering the external or internal surfaces of organs, glands, or other body structures (e.g., skin, uterus, lung, breast, prostate, stomach, bowel), and which tend to mestastasize; sarcomas, which are derived from connective or supportive tissue (e.g., bone, cartilage, tendons, ligaments, fat muscle); Carcinomas may be adenocarcinomas (which generally develop in organs or glands capable of secretion, such as breast, lung, colon, prostate or bladder) or maybe squamous cell carcinomas (which originate in the squamous epithelium and generally develop in most areas of the body). Sarcomas may be osteosarcomas or osteogenic sarcomas (bone), chondrosarcomas (cartilage), leiomyosarcomas (smooth muscle), rhabdomyosarcomas (skeletal muscle), mesothelial sarcomas or mesotheliomas (membranous lining of body cavities), fibrosarcomas (fibrous tissue), angiosarcomas or hemangioendotheliomas (blood vessels), liposarcomas (adipose tissue), gliomas or astrocytomas (neurogenic connective tissue found in the brain), myxosarcomas (primitive embryonic connective tissue), ormesenchymous or mixed mesodermal tumors (mixed connective tissue types). In addition, solid tumours include mixed type cancers, such as adenosquamous carcinomas, mixed mesodermal tumors, carcinosarcomas, orteratocarcinomas

[0061 ] Hematologic tumours are derived from bone marrow and lymphatic tissue. Hematologic tumours may be myelomas, which originate in tiie plasma cells of bone marrow; leukemias which may be "liquid cancers" and are cancers of the bone marrow and may be myelogenous or granulocytic leukemia (myeloid and granulocytic white blood cells), lymphatic, lymphocytic, or lymphoblastic leukemias (lymphoid and lymphocytic blood cells) or polycythemia vera or erythremia (various blood cell products, but with red cells predominating); or lymphomas, which maybe solid tumors and which develop in me glands or nodes of the lymphatic system, and which may be Hodgkin or Non-Hodgkin lymphomas. In some embodiments, hematologic tumours, such as leukemias or lymphomas (e.g., acute lymphoblastic leukemia, acute myeloblasts leukemia, chronic myelogenous leukemia, Hodgkin's disease, multiple myeloma, non-Hodgfcin's lymphoma), are specifically excluded. Test Compounds

[0062] SHIP inhibitors according to the invention include, without limitation, molecules selective for SHIP, analogs and variants thereof, including, for example, the molecules described herein. SHIP inhibitors may be identified using a variety of techniques, including screening of combinatorial libraries or using predictive software. In general, test compounds are identified from large libraries of both natural products or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the method(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaiyotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi- synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographic Institute (Ft. Pierce, FL, USA), and PhaπnaMar, MA, USA. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

[0063] SHIP inhibitors maybe identified based upon the ability of a test compound to inhibit SHIP expression or activity, using routine methods available i the art. Identified SHIP inhibitors may be subsequently evaluated for their ability to protect hematopoietic cells, e.g., from a chemotherapeutic agent or radiation. In one embodiment, when a crude extract is found to protect hemopoietic cells, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is me careful characterization and identification of a chemical entity within the crude extract having protective, e,g,, myeloprotective, activities, The same assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fr actionation and purification of such heterogeneous extracts are known in the art lf desired, compounds shown to be useful agents for treatment are chemically modified according to methods known in the art. Compounds identified a$ being of therapeutic, prophylactic, diagnostic, or other value may be subsequently analyzed using a SHIP knockout animal model, or any other animal model suitable for immune suppression or myelosuppression.

£bemotherapeutic Agents

[0064] A "chemotherapeutic agent" or "chemotherapeutic" refers to a chemical compound or composition that may be used to treat a disease in a patient. In alternative embodiments, chemotherapeutics include cancer chemoύierapeutics. In alternative embodiments, chemotherapeutics include alkylating and oxidizing agents, antimetabolites, antibiotics, mitotic inhibitors, chromatin function inhibitors, hormone and hormone inhibitors, antibodies, immunomoduktors, angiogenesis inhibitors, rescue/protective agents, etc.

[0065] Alkylating and oxidizing agents include nitrogen mustards, ethylenimines, alkyl sulfonates, nitrosureas, triazenes, platinum coordinating complexes, etc. Nitrogen mustards include mechlorethamine (Mustargen™), cyclophosphamide (Cytoxan™ and Neosar ifosfamide (Ifex™), phenylalanine mustard, melphaleo (Alkeran™), chlorambucol (Leukeran™), uracil mustard and estramustine (Emcyt™); ethylanhtiines include thiotepa (Thioplex™); alkyl sulfonates include busulfan

(Myerlan™); nitrosureas include lomustine (CeeNU™), carmustijtie (BiCNU™ and BCNU™) streptozocin (Zanosar™), etc.; triazinea include dicarbazine (DTIC-Dome™), temozolamide (Temodar™), etc.; platinum coordination complexes include cis-platmum, cisplatin (Platinol™ and Platmol AQ™), carboplatin (Paraplatin™), etc. Other examples of alkylating and oxidizing agents include altretamine (Hexalen™) and arsenic (Tnseπox™).

[0066] Antimetabolites include folic acid analogs, pyrimidine analogs and purine analogs. Folic acids include methotrexate (Amethopterin™, Folex™, Mexate™, Rheumatrex™), etc.; pyrimidine analogs include 5-fluoraraeil (Adπicil™, Efixdex™, Fluoroplex™), floxuridine, 5-fluorodeoxyuridine (FUDR™), capecitabine (Xeloda™), fhirdarabine (Fludara™), cytosine arabinoside (Cytaribbe™, Cyrosar™, ARA-C™), etc.; purine analogs include 6-mercaptopurine (P ri nethol) 6-thioguanine (Thiogua πine™), gemcitabine (Gemzar™), cladribine (Leustatin™), deoxycofo πnycin andpentostatin (Nipent™), etc.

[0067] Antibiotics include doxorubicin (Adriamycin™, Rubex™, Doxil™, Daunoxome™-liposomal preparation), daunorubicin (Daunomycin™, Cerubidi πe™), idarabicin (Idamycin™), valrubicin (Valstar™), epirubitin, mitoxantrone (Novantrone™), dactinomycin (Actiaomycin D™, Cosmegeri™), mitbramycin, plicamycin (Mithracin™), mitomycin C (Mutamycin™), bleomycin (Blenoxane™), procarbazine (Matulane™), etc.

[0068] Mitotic inhibitors include tøxanes or dϊterepenes and vinoa alkaloids. Examples of taxanes include paditaxel (Taxol™) and docetgxel (Taxotere™). Examples of vinoa alkaloids include vinblastine sulfate (Velban**1, Velsar™, VLB™), vincristine sulfate (Oncovin™, Vincasa PFS™, Vincrex™) and vinorelbine sulfate (Navelbine™).

[0069] Chromatin function inhibitors include camptothecins and epipodophyllotoxins. Examples of camptothecins include topotecan (Caraptosar™) and irinotecan (Hycamtin™). Examples of epipodophyllotoxins include etoposide (VP-1 6™, VePesid™ and Toposar™*) and teniposide (VM-26™ and Vumon™).

[0070] Hormone and hormone inhibitors include estrogens, antiestrogens, aromatase inhibitors, progestins, GnRH agonists, androgens, antiandiogens and inhibitors of syntheses, Examples of estrogens include diethylstilbesterol (Stilbesterol™ and Stilphostrol™), estradiol, estrogen, esterified estrogens (Estratab™ and Menest™) and estramustine (Emcyt™). Examples of anti-estrogens include tamoxifin (Nolvadex™) and toremifene (Fareston™). Examples of aromatase inhibitors include anastrozole (Arimidex™) and letrozol (Femara™). Examples of progestins include 17-θH-ρrogesterone, medroxyprogesterone, and megastrol acetate (Megace™). Examples of GnRH agonists include gosereline (Zoladex™) and leuprolide (Leupron™). Examples of androgens include testosterone, methyltestosteraae and fluoxmesterone (Android-F™, Halotestin™). Examples of aπtiandrogens include flutamide (Eulexin™), bicalutamide (Casodex™) and nilutamide (Nilandron™). Examples of inhibitors of synthesis include aminoglutethimide (Cytadren™) and ketoconozole (Nizoral™).

[0071] Antibodies include rituximab (Rituxan 1 trastuzumab (Herceptin™), gemtuzumab ozogamicin (Mylotarg™), tositumomab (Bexxar™) and bevacizumab. These chemotherapeutics may be antibodies that are targeted to a particular pnjtein on the cell surface of a cancer cell, These antibodies may provide a motif for generating an immune response to the antibody and hence the cancer cell or possibly induce apoptosis. Other mechanisms of action of this class of chemotherapeutic include inhibiting stimulation from growth factors by binding to receptors on cancer cells.

[0072] Immunomodulators include denileukin diftitox (Ontak™), levami$ole (Ergamisol™), bacillus Calmette-Gueran, BCG (TheraCys™, TICE BCG™), interferon alpha-2a, interferon alρha-2b (Roferon-A™, Ititron A™) and interleukin-2 and aldesleukin (ProLeukm™),

[0073] Angiogenesis inhibitors include thalidomide (Thalomid™), angiostatin and endostatin. Rescue/protective agents include dexrazoxane (Zinecard™), amifostine (Ethyol™), G-CSF (Neupogen™), GM-CSF (Leukine^M), erythopoetin (Epogen™, Procrit™), oprelveldn and IL-1 1 (Neumega™). Otlier cancer chemotherapeutics include imatmib mesylate, STI-571 (Gleevec™), 1-asρariginase (Elspar™,

M KidroIflse )5pegaspasgase (Oncaspar ™), hydroxyurea (Hydrea™, Doxia™), leucovorin (Wellcovorin™), mitotane (Lysodren™), porfimer (Photofrin™), tretinoin (Veasnoid™), oxaliplatin, etc.

[0074] In alternative embodiments, compositions according to the invention may be administered in combination with radiotherapy or a chemotherapeutic agent, such as a cancer therapeutic, as described herein or known in the art In alternative embodiments, the chemotherapeutic is known to induce immune suppression or myelosuppressio π. In alternative embodiments, the chemotherapeutic is suspected of causing, or belongs to a class of compounds that induce, immune suppression or myelosuppression.

Pharmaceutical Compositions and Administration

[0075] SHIP inhibitors may be provided alone or in combination with other compounds (for example, chemotherapeutics), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to mammals, for example, humans, cattle, sheep, etc. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for immune suppression or myelosuppression. SHIP inhibitors may also be provided in combination with radiotherapy.

[0076] SHIP inhibitors may be provided chronically or intermittently. "Chronic*1 administration refers to administration of the agent(s) i a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature, In alternative embodiments, SHIP inhibitors are administered to a subject in need of such inhibitors, e.g., a subject undergoing a chemotherapy or a radiotherapy, or any therapy likely to cause depletion of hemopoietic cells, such as HPCs. In alternative embodiments, SHIP inhibitors may be administered to a subject for short periods of time e.g, 1 or 2 days, or up to 48 hours, or for sufficient time to protect HPCs. fa alternative embodiments, SHIP inhibitors may be administered to a subject before or during a chemotherapy or a radiotherapy, or any therapy likely to cause depletion of hemopoietic cells, such as HPCs. In alternative embodiments, SHIP inhibitors may be administered to a subject after a chemotherapy or a radiotherapy, or any therapy likely to cause depletion of hemopoietic cells.

[0077] In alternative embodiments, a SHIP inhibitor, e.g., a siRNA selective for SHIPl, may be effectively delivered to haempoietic cells by a variety of methods known to those skilled in the art. Such methods include but are not limited to liposomal encapsulation/delivery, vector-based gene transfer, fusion to peptide or immunoglobulin sequences for enhanced cell targeting and other techniques. [0078] In alternative embodiments, a SHIP inhibitor, e,g,t an siRNA selective for

SHIPl 3may also be formulated in pharmaceutical compositions well known to those in the field. These include liposomal formulations and combinations with other agents or vehicjes/excipients such as cyclodextrins which may enhance delivery of the active siRNAJn alternative embodiments, suitable carriers include lipid-based carriers such as a stabilized nucleic acid-lipid particle (e.g,, SNALP or SPLP), cationic lipid or liposome nucleic acid complexes (i.e., lipoplexes), a liposome, a micelle, a virosome, or a mixture thereof. In other embodiments, the carrier system is a polymer-based carrier system such as a cationic polymer-nucleic acid complex (Le., polyplex). In alterative embodiments, the carrier system is a cyclodextrin-based carrier system such as a cyelodextrin polymer-nucleic acid complex, In further embodiments, the carrier system is a protein-based carrier system such as a cationic peptide-nucleic acid complex,

[0079] Suitable carriers are known in the art and are described in, without limitation, United States Patent Application Nos. 20070 173476 published July 26, 2007; 20050008617 published January 13, 2005; 20050014962 published January 20, 2005; 20050064595 published March 24, 2005; 20060008910 published January 12, 2006; 20060051405 published March 9 2006; 20060083780 published April 20, 2006; 20050008689 published January 13, 2005; 20070172950 published July 26, 2007; United States Patent Nos, 7,101,995 issued September 5 2006 to Lewis, et al,; 7,220,400 issued May 22, 2007, to Monahan, et al.; 5,705,385 issued January 6, 1998 to Bally, et al.; 5,965,542 issued October 12, 1999 to Wasan, et al.; 6,287,591 issued September 11, 2001 to Semple, et al., all of which are hereby incoiporated by reference.

[00SO] In one embodiment, the present invention contemplates a nucleic acid-lipid particle comprising a nucleic acid inhibitor of a SHIP, such as an siRNA specific for a SHIP, e.g., SHIPl , In addition to the references described above, suitable nucleic acid-lipid particles and their use are described in U.S. Patent Nos. 6,81 5,432, 6,586,410, and 6,534,484. In particular embodiments, the nucleic acid-lipid particle comprises a nucleic acid inhibitor of SHIP, a cationic lipid, and a modified lipid that prevents aggregation of particles. The particle may further comprise a non-catiom'c lipid, ϊπparticular embodiments, Hie nucleic acid inhibitor of SHIP is an antiseπse oligonucleotide, an siRNA, or a miRNA that specifically targets a SHEP polynucleotide.

[0081] Conventional pharmaceutical practice maybe employed to provide suitable formulations or compositions to administer the compounds to subjects suffering from, at risk of, or presymptoinatic for immune suppression or myelosuppression. Suitable pharmaceutical compositions may be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner, Any appropriate route of administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, iπtratisternal, intraperitoneal, intranasal, aerosol, lavage, topical, oral administration, or any mode suitable for the selected treatment. Therapeutic formulations maybe in the form of liquid solutions or suspensions. For enteral administration, the compound maybe administered in a tablet, capsule or dissolved in liquid form. The table or capsule may be enteric coated, or in a formulation for sustained release. For intranasal formulations, in the form of powders, nasal drops, or aerosols. For parenteral administration, a compound may be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water soluble compounds such as those used for vitamin KL

[0082] Methods well known in the art for making formulations are found in, for example, Remington: the Science ά Practice of Pharmacy by Alfonso Gennaro, 20th ed., Williams Wilkins, (2000). Formulations for parenteral administration may, for example, contain excipieπts, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers maybe used to control the release of the compounds. Other potentially useful parenteral delivery systems for include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. For therapeutic or prophylactic compositions, the compounds are administered to an individual in, an amount sufficient to stop or slow hemopoietic cell death, or to enhance the proliferation of hemopoietic cells.

[0083] An ''effective amount" of a compound according to the invention includes a therapeutically effective amount or a piophylactically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as treatment of immune suppression or myelosuppression. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects, A "prophylactically effective amount" refers t an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as prevention or protection against hemopoietic cell death or maintenance of hemopoietic cells. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount, A preferred range for therapeutically or prophylactically effective amounts of a compound may be any integer from OΛnM-O.lM, 0.1 nM-0.05M, 0.05 nM-15uM or 0.01 nM-10µM.

[0084] It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound(s) in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response, For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.

[0085] As used herein, a subject may be a human, non-human primate, rat, mouse, cx)w, horse, pig, sheep, goat, dog, cat, etc. The subject may be a clinical patient, a clinical trial volunteer, an experimental animal, etc. The subject maybe suspected of having or at risk for immune suppression or myelosuppression, be diagnosed with immune suppression or myelosuppression, or be a control subject that is confirmed to not have immune suppression or myelosuppression. Diagnostic methods for immune suppression or myelosuppression and the clinical delineation of immune suppression or myelosuppression diagnoses are known to those of ordinary skill in the art.

[0086] The present invention will be farther illustrated in the following examples.

EXAMPLE 1: siRNA mediated knock-down of SHIP expression enhances PIF3 dependent signaling

[0087] Small interfering (si)RNAs were demonstrated to markedly reduce SHIP levels when transfected into the human erythroleukeπu'c cell line, TFl , or the mouse cell line, EL-4. More specifically, various siRNAs selective for mouse and human SHIP 1 sequences were tested.

[0088] The following siRNAs (with their position relative to the target sequence indicated) were directed against the sequence described in GenBank Accession No. U51742, which describes mouse SHIP mRNA:

SHJPl(aSHIP): CCC ACT AGT TGT TGA ACT TTA (SEQ ID NO: 5)

SHIP2(2080): AAC AGG GAT GAA GTA CAA CTT (SEQ ID NO: 6)

SHIP3(1 509): AAG TCA CCA GCA TGA CAT TTA (SEQ ID NO: 7)

SHIP4(2991): AAC CAC CTC TGT CGC CAA AGA (SEQ ID NO: 8)

SHIP2a (AS/188): ATG GAC TCG CTG GCA CGC A C (SEQ ID NO: 9)

SHIPla(238l): AAG AGT CAG GAA GGA GAG AAT (SEQ ID NO; 10) [0089] The following siRNAs (with their position relative to the target sequence indicated) were directed against the sequence described in GenBank Accession No. NMLOOlO-7915, which describes human SHIP mRNA:

C) 2437-AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11) B) 1749-AACCTCCTTAGGGTTCGTCAA (SEQ ID NO: 12) A) 359-AAGGCGTCTCCATGAGGTTCT (SEQ ID NO 13) I D) 2728-AAGACGAGGGAGAAGCTCTAT (SEQ ID NO: 14)

[0091] EL-4 (mouse) or TFl (human) hemopoietic progenitor lines were transduced with the indicated siRNAs to SHIPl or a control non-silencing siRNA (NS or siNS), Cell lysates were prepared on the indicated days and assessed for SHIPl and control GAPDH protein expression by immunoblot analyses (Figs. IA-C, siRNA to mouse SHIPl in EL-4 cells; Figs. ID-E, siRNA to human SHIPl in TF-I cells).

[0092] TFl cells transfeαed with siSHIP (AAGAGTCAGGAAGGAGAAAAT, SEQ ID NO: 11 ) or siNS were stimulated with the cytokine GM-CSF for the indicated length of time. Cell lysates were prepared and subjected to immunoblot analysis with antibodies against SHIP, the PIP3 dependent kinase PKB or phospho PKB (Ser 473) (Fig. IB), siRNAs effectively reduced SHIPl levels, as assessed by both Western analysis (Figs. IA-E). Inhibition of SHIPl expression enhanced the activation of the PIP3 dependent kinase PKB (Fig. IF).

EXAMPLE 2: siRNA mediated inhibition of SHIPl expression enhances cell survival and proliferation

[0093] TFl cells transfected with siSHIP (triangles) or siNS (squares) were cultured in the absence of growth factors and the total number of viable cells counted daily by trypan blue exclusion (Fig. IG), TFl cells were cultured in the presence of increasing concentrations of the growth promoting cytolcine IL-5, 2 days after siRNA transection. Proliferation of siSHIP (diamonds) and control siNS (solid diamonds) transfected TF-I cells was measured by [3H]-thymidine incorporation (Fig, IH). Inhibition of SHIP expression considerably increased survival of these cells (Fig, IG) and proliferation in response to sub-optimal levels of IL-5 (Fig. IH). EXAMPLE 3: siRNA-mediated knock-down of SHIPl expression enhances resistance to chemotherapy drugs.

[0094] The TF I hemopoietic progenitor cell line was transfected with SHIP 1 siRNA or control siRNA as in Fig. 1. After 4 days, the cells were assessed at the indicated concentrations of cisplatin, doxorubicin and taxotere in the presence of complete growth media, [3H]-thymidine incorporation was measured 2 days later. The results indicate that TFl cells in which SHIPl is silenced are significantly more resistant to three common chemotherapy drugs vised to treat solid tumours (Fig. 2).

REFERENCES

I. Sly LM Rauh MJ, Kalesnikoff J5 Buchse T, Krystal G, SHIP 1 SH1P2 and PTEN activities are regulated in vivo by modulation of their protein levels; SHIP is upregulated in macrophages and mast cells by lipopolysaccharide.

ExpHematol. 2003;31 :1170-1181.

2. Helgason CD5 Damen JE Rosten P, et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. l998;12:l όl(M ό20, 3. Liu L, Damen JE, Huber M, et al. SHIP accelerates ceramide induced apoptosis in hemopoietic cell lines [abstract]. Blood, 1 997;90,307a.

4. Liu Q, Sasaki T5Kozieradzki I, et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999; 13:786-791. 5. Wang H, Li M, Rinehart JJ, Zhang R, Dexamethasone as a chemoprotecta πt in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of caϊboplatm and gemcitabine. Cancer Chemother Pharmacol. 2004;53 :459-407, 6. Sorrentino BP . Gene therapy to protect haematopoietic cells from cytotoxic cancer drags. Nat Rev Cancer. 2002;2:43 1-441 . 7. Rosenfeld CS, Nemunaitis J. The role of granulocyte-macrophage colony-stimulating factor-stimulated progenitor cells in oncology. Semin HematoL

1992;29:l ~2ø\

8. Bronchud MH, Howell A, CrowtherD, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989,60:121-125. 9. Armitage JO. Emerging applications of recombinant human

granulocyte-macrophage colony-stimulating factor. Blood. 1 _)B;92:44S>1 -4508, S 10. Armstrong DK, Davidson NE. Dose intensity for breast cancer. Oncology (WiUiston Park), 2001;15:701-8, 712. 11. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function, J Biol Chem. 1999;274:8347-8350. 12. Maxwell MJ, Yuan Y Anderson KE Hibbs ML, Salem HH, Jackson 0 SP. SHIPl and lyn kinase negatively regulate integrin allbb3 signalling in platelets, J Biol Chem. 2004;279:32 196-32204. 13. Riesterer O, Tenzer A, Zingg D, et al. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PBK/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy? Int 5 J Radiat Oncol Biol Phys. 2004,58:361 -368.

14. Kim IA, Bae SS, Fernandas A et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isofoπns increases ihe radiosensitivity of human carcinoma cell lines. Cancer Res. 2005;65r7902-7910.

15. Coffey JC Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase 0 accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy.induced apoptosis. Novel role for an old enemy. J Biol Chem. 2005;280:20908-20977.

16. Tu Z3 Ninos JM3 Ma Z, et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phos ρhatase isofoim that partners with the 5 Grb2 adapter protein, Blood. 2001;98;2028-2038.

17. Kim CH, Hangoc G, Cooper S et al. Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest. 1999;lO4:1751-1759

18. Sly LM, Rauh MJ, Kalesnikoff J, Song CH 3 Krystal G, LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity, 2004;21 :227-239.

1 - Gardai S, Whitlock BB, Helgason C, et al. Activation of SHIP by NADPH oxidasestimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002;277:5236-5246. 20. CoxD,DaleBM 5KashiwadaM,,HelgasonCD, GreenbergS. Aregulatory role for Src homology 2 domain-containing inositol 5'- phosphatase (SHIP) in phagocytosis mediated by Fcg receptors and complement receptor 3 (aMb2; CDl 1 b/CDl 8). J Exp Med. 2001; 193:61-7U

21. Mason JM1 Halupa A, Hyam D, Iscove NN, Dumont DJ, Barber DL. SHIPl regulates the proliferation and mobilization of the erythroid lineage [abstract]. Blood.2002; 100,51 9a

[0095] AUcitations are hereby incorporated by reference.

[0096] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims. WHAT IS CLAIMED IS:

1. A method of protecting a hemopoietic cell in a subject in need thereof, the method comprising administering an effective amount of an inhibitor of a hemopoietic-restricted SH2-containing inositol-5 '-phosphatase to said subject.

2. The method of claim 1 wherein the hemopoietic cell is a hemopoietic progenitor cell.

3. The method of claim 2 wherein the hemopoietic progenitor cell is a myeloid progenitor cell or a lymphoid progenitor cell.

4. The method of claim 1 wherein the hemopoietic cell is a mature cell.

5. The method of any one of claims 1 to 4 wherein the protecting comprises decreasing cell death.

6. The method of claim 5 wherein the cell death comprises apoptosis.

7. The method of claim 6 wherein the cell death is induced by chemotherapy or by radiotherapy.

8. The method of any one of claims 1 to 7 wherein the hemopoietic-restricted SH2-containing inositol-5 '-phosphatase is a SHIPl molecule.

9. The method of any one of claims 1 to 8 wherein the subject has, or is suspected of having, a cancer.

10. The method of claim 9 wherein the cancer comprises a solid tumor.

11. The method of any one of claims 1 to 10 wherein the subject is a human.

12. The method of any one of claims 1 to 11 wherein the subject is undergoing chemotherapy or radiotherapy.

13. The method of claim 12 wherein the chemotherapy is a cancer therapy.

14. The method of claim 13 wherein the cancer therapy is selected from the group consisting of one or more of cisplatin, doxorubicin, and taxotere. 15. The method of any one of claims 1 to 14 further comprising administering a chemotherapeutic agent or administering a radiotherapy.

16. The method of claim 15 wherein the chemotherapeutic agent is a cancer therapeutic agent.

17. The method of claim 16 wherein the cancer therapeutic agent is selected from the group consisting of one or more of cisplatin, doxorubicin, and taxotere.

18. The method of claim 17 wherein said inhibitor is administered before, during or after administration of said chemotherapeutic agent or said radiotherapy.

19. The method of any one of claims 1 to 18 wherein the inhibitor is a siRNA or a small molecule.

20. The method of claim 19 wherein the siRNA consists essentially of the sequence AAGAGTCAGGAAGGAGAGAAT (SEQ ID NO: 10) or

AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11).

2 1. A method of treating myelosuppression in a subject in need thereof, comprising administering an effective amount of an inhibitor of a hemopoietic- restricted SH2-containing inositol-5' -phosphatase to said subject.

22. The method of claim 2 1 wherein the myelosuppression comprises immune suppression.

23. The method of claim 2 1 wherein the myelosuppression comprises a decrease in hemopoietic progenitor cells or mature cells.

24. The method of any one of claims 2 1 to 23 wherein the treating comprises increasing proliferation of a hemopoietic cell.

25. The method of any one of claims 2 1 to 24 wherein the treating comprises reducing death of a hemopoietic cell.

26. The method of any one of claims 2 1 to 25 wherein the myelosuppression is induced by chemotherapy or by radiotherapy. 27. The method of any one of claims 2 1 to 26 wherein the hemopoietic- restricted SH2-containing inositol-5 '-phosphatase is a SHIPl molecule.

28. The method of any one of claims 2 1 to 27 wherein the subject has, or is suspected of having, a cancer.

29. The method of claim 28 wherein the cancer comprises a solid tumor.

30. The method of any one of claims 2 1 to 29 wherein the subject is a human.

31. The method of any one of claims 2 1 to 30 wherein the subject is undergoing chemotherapy or radiotherapy.

32. The method of claim 31 wherein the chemotherapy is a cancer therapy.

33. The method of claim 32 wherein the cancer therapy is selected from the group consisting of one or more of cisplatin, doxorubicin, and taxotere.

34. The method of any one of claims 31 to 33 wherein said inhibitor is administered after administration of said chemotherapy or said radiotherapy.

35. The method of any one of claims 2 1 to 34 wherein the inhibitor is a siRNA or a small molecule.

36. The method of claim 35 wherein the siRNA consists essentially of the sequence AAGAGTCAGGAAGGAGAGAAT (SEQ ID NO: 10) or

AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11).

37. A siRNA molecule consisting essentially of the sequence AAGAGTCAGGAAGGAGAGAAT (SEQ ID NO: 10) or

AAGAGTCAGGAAGGAGAAAAT (SEQ ID NO: 11).

38. A pharmaceutical composition comprising the molecule of claim 37 in combination with a pharmaceutically acceptable carrier.

39. The pharmaceutical composition of claim 40 further comprising a chemotherapeutic agent. 40. The pharmaceutical composition of claim 39 wherein the chemotherapeutic agent is selected from the group consisting of one or more of cisplatin, doxorubicin, and taxotere.

4 1. A kit comprising the molecule of claim 37, together with instructions for use in treating myelosuppression.

42. Use of an inhibitor of a SH2-containing inositol-5' -phosphatase in the preparation of a medicament for protecting a hemopoietic cell in a subject in need thereof.

43. Use of an inhibitor of a SH2-containing inositol-5 '-phosphatase in the preparation of a medicament for treating myelosuppression in a subject in need thereof.

44. The use of claim 45 wherein the myelosuppression comprises immune suppression.

45. A method for screening for an inhibitor of a hemopoietic-restricted SH2- containing inositol-5 '-phosphatase, the method comprising: i) providing a test compound and a control compound; ii) contacting a hemopoietic cell with the test compound or the control compound; and iii) determining whether the test compound is capable of increasing the survival or proliferation of the hemopoietic cell compared to the control compound; wherein a test compound that increases the survival or proliferation of the hemopoietic cell compared to the control compound is an inhibitor of a SH2-containing inositol-5 '-phosphatase

A . CLASSIFICATION OF SUBJECT MATTER IPC: C07H 21/02 (2006.01) , A61K 31/7105 (2006.01) , A61K 48/00 (2006.01) , A61P 37/02 (2006.01) , C12N 15/55 (2006.01) , C12N 9/16 (2006.01) C12Q 1/02 (2006.01) , C12Q 1/18 (2006.01) , C12Q 1/42 (2006.01) , A61K 31/704 (2006.01), /467^37/337(2006.01) , A61K 33/24 (2006.01)

B . FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC: C07H 21/02 (2006.01) , A61K 31/7105 (2006.01) , A61K 48/00 (2006.01) , A61P 37/02 (2006.01) , C12N 15/55 (2006.01) , C12N 9/16 (2006.01) C12Q 1/02 (2006.01) , C12Q 1/18 (2006.01) , C12Q 1/42 (2006.01) , A61K 31/704 (2006.01), /467^37/337(2006.01) , A61K 33/24 (2006.01) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Delphion, Scopus, CAplus, Pubmed, Genome Quest Keywords: SHLP, inhibitor, hemopoietic, hematopoietic, myelosuppression, siRNA, protection, ed), chemotherapy

C . DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X, P US 2006/0223749 A l (UNIVERSITY OF SOUTH FLORIDA) 5 October 2006. 1 to 19, 2 1 to 35 and 4 1 to 45 Whole Document

A US 6,841,532 B2 (CV MOLECULAR THERAPEUTICS, INC.) 11 January 2005. 1 to 45 Whole Document

A WO 03/033517 A l (THE UNIVERSITY OF BRITISH COLUMBIA) 24 April 1 to 45 2003. Whole Document

A WO 2004/032880 A2 (ISIS PHARMACEUTICALS, INC.) 22 April 2004. l to 45 Whole Document

A WO 02/24233 A2 (UNIVERSITY OF SOUTH FLORIDA) 28 March 2002. l to 45 Whole Document

[X] Further documents are listed in the continuation of Box C . [X ] See patent family annex.

* Special categories of cited documents "T" later document published after the international filing date or priority date and not m conflict with the application but cited"to understand "A" document defining the general state of the art which is not considered the principle or theory underlying the invention to be of particular relevance "X" document of particular relevance, the claimed invention cannot be "E" earlier application or patent but published on or after the international considered novel or cannot be considered to involve an inventive filing date step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is "Y" document of particular relevance, the claimed invention cannot be cited to establish the publication date of another citation or other considered to involve an inventive step when the document is special reason (as specified) combined with one or more other such documents, such combination being obvious to a person skilled m the art "O" document referring to an oral disclosure, use, exhibition or other means "&" document member of the same patent family "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report

15 November 2007 (15-1 1-2007) 4 December 2007 (04-12-2007) Name and mailing address of the ISA/CA Authorized officer Canadian Intellectual Property Office Place du Portage I, Cl 14 - 1st Floor, Box PCT Nathalie Chartrand 819- 994-234 1 50 Victoria Street Gatineau, Quebec KlA 0C9 Facsimile No.: 001-819-953-2476

Form PCT/ISA/210 (second sheet ) (April 2007) Page 4 of 6 Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet) This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. [X] Claim Nos 1 to 36 because they relate to subject matter not required to be searched by this Authority, namely

Claims 1 to 36 are directed to a method for treatment of the human or animal body by surgery or therapy, which the International Search Authority is not required to search Regardless, this Authority has carried out a search based on the alleged effects or purposes/uses of the product defined in claims 19, 20 and 35 to 40

2 [ ] Claim Nos because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically

Claim Nos because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

Box No. Ill Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows

1 [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims

2 [ ] As all searchable claims could be searched without effort justifying additional fees, this Authority did not mvite payment of additional fees

3 [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos

4 [ ] No required additional search fees were timely paid by the applicant Consequently, this international search report is

restricted to the invention first mentioned in the claims, it is covered by claim Nos

Remark on Protest [ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee [ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation [ ] No protest accompanied the payment of additional search fees Form PCT/ISA/2 10 (continuation of first sheet (2)) (April 2007) Page 3 of 6 C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No

A AI, J et al , "The inositol phosphatase SHIP-2 down-regulates FcγR-mediated 1 to 45 phagocytosis in murine macrophages independently of SHIP-I ", BLOOD January 2006, VoI 107, no 2, pages 813-820 Abstract

Form PCT/ISA/210 (continuation of second sheet) (April 2007) Page 5 of 6 Information on patent family members PCT/CA2007/001501

Patent Document Publication Patent Family Publication Cited in Search Report Date Member(s) Date

US 2006223749A1 05-10-2006 A U 9275301 A 02-04-2002 CA 2422868A1 28-03-2002 EP 1318841A2 18-06-2003 US 200213771 1A1 26-09-2002 US 20021 65192A1 07-1 1-2002 W O 0224233A2 28-03-2002 W O 0224233A3 13-03-2003

US 6841532B2 11-01-2005 US 5917013A 29-06-1999 US 6348567B1 19-02-2002 US 7 115562 B2 03-10-2006 US 20021 65129A1 07-1 1-2002 US 200528274 1A1 22-12-2005

W O 030335 17A1 24-04-2003 A U 20032 18843A1 04-05-2004 CA 2463136A1 24-04-2003 CA 2502293A1 29-04-2004 EP 1554304A1 20-07-2005 JP :2006506363T 23-02-2006 us 2004266865A1 30-12-2004 W O 2004035601A1 29-04-2004

W O 2004032880A2 22-04-2004 A U 2003284 140A1 04-05-2004 A U 2003284 140A8 04-05-2004 W O 2004032880A3 12-08-2004

W O 0224233A2 28-03-2002 A U 9275301 A 02-04-2002 CA 2422868A1 28-03-2002 EP 1318841A2 18-06-2003 US 200213771 1A1 26-09-2002 US 20021 65192A1 07-1 1-2002 US 2006223749A1 05-10-2006 W O 0224233A3 13-03-2003

Form PCT/ISA/210 (patent family annex ) (April 2007) Page 6 of 6